A generic version of the blockbuster cholesterol medication Restovax is set to hit pharmacy shelves next month after the FDA granted final approval to three manufacturers. The generic is expected to cost roughly 70 percent less than the brand-name version.
Restovax has been one of the most prescribed statins in the country, with over 12 million active prescriptions. Patient advocacy groups have long called for affordable alternatives as the drug's annual cost exceeded $3,000 for many uninsured patients.
Pharmacies are already placing orders in anticipation of strong demand, and insurers have indicated they will move the generic to preferred formulary tiers.
